Blood Brain Barrier Defect Clinical Trial
Official title:
Efficacy and Safety of Gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
the trial aims to evaluate the Efficacy and Safety of gadopiclenol for Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
The purpose of this trial is to evaluate a new gadolinium-based contrast agent (GBCA) gadopiclenol injection for Central Nervous System (CNS) lesion detection and visualization by conventional steady-state CNS imaging. . This is a multi-center, international, prospective, double-blind, randomized, controlled,cross-over with comparator trial in male and female patients presenting with known or highly suspected CNS lesion(s) with focal areas of disrupted Blood Brain Barrier (BBB) (e.g., primary and secondary tumors) who are scheduled to undergo a routine contrast-enhanced Magnetic Resonance Imaging (MRI) of the CNS. This trial will be conducted in approximately 40 centers worldwide. During the course of the trial, two MRIs will be obtained from each patient: one unenhanced and gadopiclenol-enhanced MRI; and one unenhanced and gadobutrol-enhanced MRI. MRI evaluations will be performed by on-site investigators and three independent off-site blinded readers. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT04096261 -
The Importance of Sleep Quality and the Blood-brain Barrier in Cognitive Disorders and Alzheimer's Disease
|
||
Completed |
NCT02633501 -
P03277 Dose Finding Study in Central Nervous System (CNS) Magnetic Resonance Imaging (MRI)
|
Phase 2 | |
Recruiting |
NCT06203015 -
The Relations Among Endotoxin, Inflammatory Cytokines, Cognitive Markers and Brain MRI Changes in Subjects With Depressive Disorder
|
||
Active, not recruiting |
NCT04876638 -
Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)
|
Phase 2 | |
Completed |
NCT03639896 -
Endothelial Injury Mechanism in Elderly Patients Undergoing Major Surgery
|
Phase 4 | |
Completed |
NCT02389738 -
Brain Interstitium Temozolomide Concentration Pre and Post Regadenoson Administration
|
Early Phase 1 | |
Completed |
NCT03139682 -
Microvascular Injury and Blood-brain Barrier Dysfunction as Novel Biomarkers and Targets for Treatment in Traumatic Brain Injury
|
||
Recruiting |
NCT05902039 -
MRI Study of Blood-brain Barrier Function in CADASIL
|